Cargando…

Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report

INTRODUCTION: Pure red cell aplasia due to anti-epoetin antibodies is a known complication of epoetin therapy for anemia due to chronic kidney disease. This disease has not previously been well described in the setting of therapy for chronic hepatitis C virus infection. While treatment for pure red...

Descripción completa

Detalles Bibliográficos
Autores principales:	Behler, Caroline M, Terrault, Norah A, Etzell, Joan E, Damon, Lloyd E
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Case report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2737792/ https://www.ncbi.nlm.nih.gov/pubmed/19830190 http://dx.doi.org/10.4076/1752-1947-3-7335

Ejemplares similares

Pure red cell aplasia induced by epoetin zeta
por: Panichi, Vincenzo, et al.
Publicado: (2016)

Rituximab: A viable treatment option for epoetin-induced pure red cell aplasia
por: Mahajan, S. A., et al.
Publicado: (2015)

Pure red cell aplasia after treatment of renal anaemia with epoetin theta
por: Herrington, W., et al.
Publicado: (2013)

Antibody-mediated pure red cell aplasia (PRCA) on switching from darbepoetin alfa to epoetin beta: what are the implications?
por: Assunção, José, et al.
Publicado: (2008)

Resolution of epoetin‐induced pure red cell aplasia, successful re‐challenge with roxadustat
por: Wu, Yunzhou, et al.
Publicado: (2020)

Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease
por: Fishbane, Steven, et al.
Publicado: (2019)

Epoetin Alfa: A Cause of Coronary Artery Thrombosis
por: Siddiqui, Muhammad Umer, et al.
Publicado: (2017)

Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial
por: Sörgel, Fritz, et al.
Publicado: (2009)

Critical Role of Iron in Epoetin Alfa Treatment of Chemotherapy-Associated Anemia
por: Gross, Irwin, et al.
Publicado: (2016)

Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
por: Arrieta, Javier, et al.
Publicado: (2014)

Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study
por: Santos, E.J.F., et al.
Publicado: (2018)

Antibody-mediated pure red cell aplasia related with epoetin-beta pegol (C.E.R.A.) as an erythropoietic agent: case report of a dialysis patient
por: Shingu, Yasuki, et al.
Publicado: (2020)

Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study
por: Stoppa, Giovanna, et al.
Publicado: (2018)

Darbepoetin Versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment
por: Ots, Pilar Ma Samper, et al.
Publicado: (2008)

Tungsten-Induced Denaturation and Aggregation of Epoetin Alfa During Primary Packaging as a Cause of Immunogenicity
por: Seidl, Andreas, et al.
Publicado: (2011)

Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients
por: Prasad, Bhanu, et al.
Publicado: (2020)

Surgical prescription of epoetin alfa in contemporary total hip arthroplasty: a prospective comparative study
por: Hourlier, Hervé, et al.
Publicado: (2019)

Successful Prolonged Desensitization to Epoetin-Alfa Hypersensitivity in an Adult Patient With Advanced Chronic Kidney Disease
por: Panchal, Hemali, et al.
Publicado: (2023)

Quality of Original and Biosimilar Epoetin Products
por: Brinks, Vera, et al.
Publicado: (2010)

TSAT is a better predictor than ferritin of hemoglobin response to Epoetin alfa in US dialysis patients
por: Gaweda, Adam E, et al.
Publicado: (2014)

Epoetin Alpha and Epoetin Zeta: A Comparative Study on Stimulation of Angiogenesis and Wound Repair in an Experimental Model of Burn Injury
por: Irrera, Natasha, et al.
Publicado: (2015)

Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial
por: Wilkinson, P M, et al.
Publicado: (2006)

Adding Epoetin Alfa to Intense Dose-Dense Adjuvant Chemotherapy for Breast Cancer: Randomized Clinical Trial
por: Moebus, Volker, et al.
Publicado: (2013)

Arterial and venous thrombosis complicating coronary artery bypass grafting after use of epoetin alfa-epbx
por: Murillo-Berlioz, Alejandro, et al.
Publicado: (2020)

Cost-Minimization Analysis of Once-Weekly Versus Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia
por: Cremieux, Pierre Y., et al.
Publicado: (2004)

The Use of Epoetin-α in Revision Knee Arthroplasty
por: Delasotta, Lawrence A., et al.
Publicado: (2012)

Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy
por: McGarvey, November, et al.
Publicado: (2015)

Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study
por: Choi, Peter, et al.
Publicado: (2013)

The Cost-Effectiveness of Using Epoetin-Beta Versus Darbepoetin-Alfa for the Treatment of Anemia Among Chronic Hemodialysis Patients
por: AlKharboush, Hanan, et al.
Publicado: (2020)

Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies
por: Wish, Jay B., et al.
Publicado: (2019)

Recombinant human epoetin beta in the treatment of renal anemia
por: Locatelli, Francesco, et al.
Publicado: (2007)

The Use of Preoperative Epoetin-α in Revision Hip Arthroplasty
por: Delasotta, Lawrence A, et al.
Publicado: (2012)

Epoetin beta for the treatment of chemotherapy-induced anemia: an update
por: Galli, Luca, et al.
Publicado: (2015)

Acquired Pure Red Cell Aplasia Following Recombinant Erythropoietin (Darbepoetin-alfa) Therapy
por: Padhi, Somanath, et al.
Publicado: (2020)

Anti-Erythropoietin Antibody Associated Pure Red Cell Aplasia Resolved after Liver Transplantation
por: Hung, Annie K., et al.
Publicado: (2015)

A pregnant woman with thymoma-associated pure red cell aplasia
por: Shibata, Megumi, et al.
Publicado: (2022)

Comparison of the Pharmacokinetic and Pharmacodynamic Profiles of One US-Marketed and Two European-Marketed Epoetin Alfas: A Randomized Prospective Study
por: Lissy, Michael, et al.
Publicado: (2012)

Cardiovascular effects of hemoglobin response in patients receiving epoetin alfa and oral iron in heart failure with a preserved ejection fraction
por: Vullaganti, Sirish, et al.
Publicado: (2014)

Population Pharmacodynamic Modeling of Epoetin Alfa in End‐Stage Renal Disease Patients Receiving Maintenance Treatment Using Bayesian Approach
por: Nguyen, Ly Minh, et al.
Publicado: (2020)

Impact of epoetin β on quality of life in patients with malignant disease
por: Boogaerts, M, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_vin5jebbslg8dvgvo8an2qe4t5